Skip to content
    Sixty Degree Capital logo

    Sixty Degree Capital

    Toronto, CanadaFounded 2017
    sixtydegreecapital.comLinkedIn
    AIBiotech & Life SciencesCybersecurityData & AnalyticsDeveloper ToolsHealthcareInfrastructure & CloudSaaS

    Sixty Degree Capital is a Toronto-based, multi-stage venture capital firm investing in enterprise software (data & cloud infrastructure, AI, developer tools, cybersecurity) and healthcare (therapeutics, medical devices, diagnostics) from Series A through pre-IPO. The firm closed its third fund at $250M USD in November 2023.

    33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 300% year-over-year (4 deals in the last 12 months). Their most common stage is series-b (56% of deals). Average disclosed round size is $96.0M (across 24 rounds with reported amounts).

    Find people at Sixty Degree Capital on Goldilocks AI

    Portfolio

    22

    Fund Size

    $250M

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    Cheryl Kuai, Ph.D, CFA

    Cheryl Kuai, Ph.D, CFA

    Managing Director

    Vincent Ho, CPA

    Vincent Ho, CPA

    Director, Fund Operations

    Brett Liu, MEng, CFA

    Brett Liu, MEng, CFA

    Principal

    Kenneth Grisé

    Kenneth Grisé

    Principal

    Nate Xia, PhD, CFA

    Nate Xia, PhD, CFA

    Principal

    Sintia Teichman, PhD

    Sintia Teichman, PhD

    Principal

    Hoyin Yip, PhD

    Hoyin Yip, PhD

    Associate

    Jenny Lo, MBA

    Jenny Lo, MBA

    Associate

    Sarah Blicker

    Sarah Blicker

    Associate

    Lillian Yu

    Lillian Yu

    Analyst, Fund Operations

    Robert Guo, MBA

    Robert Guo, MBA

    CEO

    AN

    Alexandre Nossovskoi

    Principal - Technology Investment

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    27 investments
    CompanyRoundAmountDate
    CCrossbowSeries B—Mar 2026
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103MJan 2026
    KKinasetSeries B$103MJan 2026
    AAVantgarde Bio logoAAVantgarde BioSeries B—Nov 2025
    GlycoEra logoGlycoEraSeries B$130MMay 2025
    NextPoint Therapeutics logoNextPoint TherapeuticsSeries B$42.5MFeb 2024
    Cato Networks logoCato NetworksGrowth$238MSep 2023
    Bionaut Labs logoBionaut LabsSeries B$43.2MNov 2022
    Inspirna logoInspirnaSeries D$50MJan 2022
    AAntios Therapeutics, Inc.Series B$75MNov 2021
    AAntios Therapeutics, Inc.Series A$75MNov 2021
    T-Knife Therapeutics logoT-Knife TherapeuticsSeries B$110MAug 2021
    Turnstone Biologics logoTurnstone BiologicsSeries D$80MJul 2021
    AAntios Therapeutics, Inc.Series B$96MApr 2021
    AArcellx, Inc.Series C$115MJan 2021
    AAntios Therapeutics, Inc.Series B$96MJan 2021
    TT-KnifeSeries B$110MJan 2021
    GrubMarket logoGrubMarketSeries D$90MDec 2020
    GrubMarket logoGrubMarketSeries D$60MOct 2020
    Libra Therapeutics logoLibra TherapeuticsSeries A$29MSep 2020
    BBionyraSeries A$165M—
    Aavantgarde logoAavantgardeSeries B$141M—
    Bionyra Pharma logoBionyra PharmaSeries A$165M—
    Eclypsium, Inc logoEclypsium, IncSeries C$25M—
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103M—
    Page 1 of 2

    Top Co-Investors

    RA Capital Management9 shared
    Sofinnova Partners6 shared
    Soleus Capital5 shared
    Atlas Venture5 shared
    Schroders Capital5 shared
    Willett Advisors5 shared
    Pontifax4 shared
    Adage Capital Management4 shared
    Delos Capital4 shared
    Amzak Health4 shared
    LifeSci Venture Partners4 shared
    EQT Life Sciences4 shared
    Vivo Capital4 shared
    CaaS Capital4 shared
    Arkin Bio Ventures4 shared
    Sanofi Ventures4 shared
    GGV Capital3 shared
    Scale Venture Partners3 shared
    Celtic House Venture Partners3 shared
    Marubeni Corporation3 shared

    Last updated: 7 October 2026